STAG2 and neoplasm: Through WGS and targeted sequencing we identified recurrent inactivating mutations of STAG2. To extend our genomic analysis we performed capillary sequencing of the 33 coding exons of STAG2 in our tumor panel and in an expanded cell line panel to confirm our sequencing findings and to evaluate for additional mutations.